Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

Baptiste Pichon; Caroline Rousseau; Audrey Blanc-Lapierre; Gregory Delpon; Ludovic Ferrer; Vincent Libois; Matthieu Le Turnier; Cédric Lenoble; Caroline Bodet-Milin; David Goldenberg; Françoise Kraeber-Bodere; Stéphane Supiot

doi:10.3390/biomedicines8120548

Journal articles

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

Baptiste Pichon ^{1, 2, 3} Caroline Rousseau ^{4, 1, 2} Audrey Blanc-Lapierre ^{1, 2} Gregory Delpon ^{5, 1, 2} Ludovic Ferrer ^{4, 1, 2} Vincent Libois ^{1, 2} Matthieu Le Turnier ⁶ Cédric Lenoble ⁶ Caroline Bodet-Milin ^{4, 1, 2, 6} David Goldenberg ⁷ Françoise Kraeber-Bodere ^{4, 1, 2, 6} Stéphane Supiot ^{5, 1, 2}

1 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]

2 Service de médecine nucléaire [Saint-Herblain]

3 Clinique Pasteur [Toulouse]

4 CRCINA-ÉQUIPE 13 - Nuclear Oncology

CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers

5 CRCINA-ÉQUIPE 9 - Apoptosis and Tumor Progression

CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers

6 Service de Médecine Nucléaire [Nantes]

7 C2MI - Center for Molecular Medicine and Immunology [Mendham, NJ, USA]

Abstract : Background: Stereotactic body radiotherapy (SBRT) for vertebral metastases (VM) allows the delivery of high radiation doses to tumors while sparing the spinal cord. We report a new approach to clinical target volume (CTV) delineation based on anti-carcinoembryonic antigen (CEA) positron emission tomography (pretargeted immuno-PET; “iPET”) in patients with metastatic breast cancer (BC) or medullary thyroid cancer (MTC). Methods: All patients underwent iPET, spine magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) using 18F-deoxyglucose (FDG) for BC or 18F-dihydroxy-phenylalanine (F-DOPA) for MTC. Vertebrae locations and vertebral segments of lesions were recorded and the impact on CTV delineation was evaluated. Results: Forty-six VM eligible for SBRT following iPET were evaluated in eight patients (five BC, three MTC). Eighty-one vertebral segments were detected using MRI, 26 with FDG or F-DOPA PET/CT, and 70 using iPET. iPET was able to detect more lesions than MRI for vertebral bodies (44 vs. 34). iPET-based delineation modified MRI-based CTV in 70% (32/46) of cases. Conclusion: iPET allows a precise mapping of affected VM segments, and adds complementary information to MRI in the definition of candidate volumes for VM SBRT. iPET may facilitate determining target volumes for treatment with stereotactic body radiotherapy in metastatic vertebral disease.

Keywords : CEA CTV GTV PET-CT bispecific antibody immuno-PET radiation oncology stereotactic ablative body radiotherapy (SABR) stereotactic body radiation therapy (SBRT) targeting vertebral metastases.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadata

https://www.hal.inserm.fr/inserm-03500271
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Wednesday, December 22, 2021 - 9:41:58 AM
Last modification on : Wednesday, January 19, 2022 - 3:44:04 PM

biomedicines-08-00548-v2.pdf

Publisher files allowed on an open archive

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

File

Identifiers

Collections

Citation

Export

Metrics

Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

File

Identifiers

Collections

Citation

Export

Share

Metrics